Project Grant R21OH013130

The Department of Health and Human Services Centers for Disease Control and Prevention (National Institute for Occupational Safety and Health) awarded $252,788 to Icahn School of Medicine at Mount Sinai on September 1, 2026, under the CDC Investigations and Technical Assistance program (CFDA 93.283) to investigate mechanisms of World Trade Center dust-induced thyroid cancer progression in organoids. Performance occurs in New York, New York, with a period of performance ending August 31, 2028.

The Centers for Disease Control and Prevention, operating under the National Institute for Occupational Safety and Health, awarded New York University $243,709 on September 1, 2026, under the CDC Investigations and Technical Assistance program (CFDA 93.283) to support the WTC Survivors: Lifestyle Medicine Study. The project runs through August 31, 2028, with place of performance in New York, New York. The CDC Investigations and Technical Assistance program assists state and local health...

The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $699,794 on August 25, 2026, under the Cancer Treatment Research program (CFDA 93.395) to modulate the tumor microenvironment and enhance nanoparticle delivery to cancer cells. The project addresses limited nanoparticle efficacy in cancer therapies caused by nonspecific uptake in the mononuclear phagocyte system and interception by tumor-resident macrophages, which results in median tumor uptake of under 1...

The Centers for Disease Control and Prevention awarded New York University School of Medicine $246,434 on September 1, 2026, for a project grant investigating epigenetic pathways mediating exposure effects on breast cancer risk in World Trade Center survivors. The award funds research spanning September 1, 2026, through August 31, 2028, and is performed in New York. The project operates under CDC Investigations and Technical Assistance (CFDA 93.283), which supports investigations and...

The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $546,842 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to characterize germline determinants of tumor development and response to treatment through integration of germline, somatic, histological, and clinical data across multiple institutional cohorts. The research investigates how inherited, population-level germline variants influence tumor development and...

The Department of Health and Human Services Centers for Disease Control and Prevention awarded The Trustees of Columbia University in the City of New York $237,764 under the CDC Investigations and Technical Assistance program (CFDA 93.283) on September 1, 2026, to investigate distal airway dysfunction following childhood exposure to the World Trade Center attack and to identify predictors and clinical consequences of that dysfunction. The award funds a two-year project with performance through...

The Department of Health and Human Services Centers for Disease Control and Prevention (National Institute for Occupational Safety and Health) awarded The Research Foundation For The State University of New York, operating as Stony Brook University, $247,383 on September 1, 2026, under the Centers for Disease Control and Prevention Investigations and Technical Assistance program (CFDA 93.283) to support research on interneuronal aging in trauma-exposed World Trade Center responders. Work is...

The Centers for Disease Control and Prevention's National Institute for Occupational Safety and Health awarded Icahn School of Medicine at Mount Sinai $249,871 on September 1, 2026, to improve World Trade Center responder mental health through precision treatment of comorbid insomnia and sleep apnea under CDC Investigations and Technical Assistance (CFDA 93.283). The project runs through August 31, 2028, with performance in New York, New York. The award funds research and clinical intervention...

The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $709,145 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate senescence-modulating nanoparticles targeting P-selectin on senescent cells as a strategy to potentiate cancer immunotherapy in fibrotic tumors. The project addresses a barrier in cancer immunotherapy: many patients with solid tumors remain unresponsive to immune checkpoint blockade and CAR T cell...

The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $366,662 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop statistical methodologies for mediation analysis using data from multiple incomplete sources in epidemiologic research. The project addresses a gap in current epidemiologic practice: existing mediation analysis methods require all three relevant variables (exposure, mediator, and outcome) to be present in a...